Italia markets close in 7 hours 12 minutes

HOWL Oct 2024 7.500 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,50000,0000 (0,00%)
In data: 10:46AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente1,5000
Aperto1,5000
Denaro0,0000
Domanda2,2500
Prezzo d'esercizio7,50
Scadenza2024-10-18
Min-Max giorno1,5000 - 1,5000
Contratto - Min-MaxN/D
Volume10
Open Interest73
  • GlobeNewswire

    Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

    Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC annual meetingCompany to present interim first-in-human clinical data from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 WATERTOWN, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated t

  • GlobeNewswire

    Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

    Virtual event to be held on Monday, September 18, 2023, at 10:00 am ETWATERTOWN, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it will host a virtual R&D Event on Monday, September 18, 2023, at 10:00 am ET. The event will fe

  • GlobeNewswire

    Werewolf Therapeutics to Participate in Upcoming Investor Conferences

    WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will participate in the following upcoming investor conferences in the month of September: H.C. Wainwright Annual Global Investor ConferenceDate: Monday, Se